| 货号 | AF744-SP |
| 别名 | MGC129934; MGC129935; TL1A; TL1Vascular endothelial cell growth inhibitor; TNF superfamily ligand TL1A; TNFSF15; tumor necrosis factor (ligand) superfamily, member 15; tumor necrosis factor ligand superfamily member 15; vascular endothelial growth inhibitor-192A; VEGI; VEGI192A; VEGITNF ligand-related molecule 1 | 全称 | TNF-like 1 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunohistochemistry(3-15 µg/mL) |
| 目标/特异性 | Detects human TL1A in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross‑reactivity with recombinant mouse TL1A is observed, and less than 2% cross‑reactivity with recombinant human (rh) APRIL, rhTNF-alpha, and rhFas Ligand is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunohistochemistry: 3-15 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 9966 (Human); 326623 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant human TL1 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | TL1A is a type II transmembrane protein belonging to the TNF superfamily and has been designated TNF superfamily member 15 (TNFSF15). Human TL1A is a 251 aa protein consisting of a 35 aa cytoplasmic domain, a 24 aa transmembrane region and a 192 aa C-terminal extracellular domain. It is a longer variant of the previously cloned TL1 (also known as VEGI) that is possibly a cloning artifact. TL1A is predominantly expressed in endothelial cells and its expression is inducible by TNF-alpha and IL-1 alpha. TL1A binds with high affinity to death receptor 3 (DR3), which is now designated TNF receptor superfamily member 25 (TNFRSF25). DR3 was formerly designated TNFRSF12 when it was thought to be the receptor for TWEAK/TNFSF12. DR3 is expressed primarily on activated T cells. Depending on the cell context, ligation of DR3 by TL1A can trigger one of two signaling pathways, activation of the transcription factor NF-kappa-B or activation of caspases and apoptosis. On primary T cells, TL1A induces NF-kappa-B activation and a costimulatory signal to increase IL-2 responsiveness and the secretion of proinflammatory cytokines. However, in a tumor cell line, TF-1, TL1A has been shown to induce caspase activity and apoptosis. These effects of TL1A are blocked by the secreted, soluble decoy receptor 3 (DcR3), also known as TR6 and TNFRSF6B, which compete with DR3 for binding to TL1A. Consistent with the observed in vitro activities, TL1A promotes ex vivo splenocyte expansion and enhances in vivograft-versus-host-response. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
TL1A/TNFSF15 in Human Prostate. TL1A/TNFSF15 was detected in immersion fixed paraffin-embedded sections of human prostate using Goat Anti-Human TL1A/TNFSF15 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF744) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections. |
